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Abstract 
We report a case of Langerhans cell histiocytosis in a 64-year-old male who presented with 
symptoms and signs of brain involvement, including seizures and hypopituitarism. The diag-
nosis was confirmed with a biopsy of a lytic skull lesion. The disease affecting the bone 
showed no sign of progression following a short course of cladribine. Signs of temporal lobe 
involvement led to an additional biopsy, which showed signs of nonspecific neurodegenera-
tion and which triggered status epilepticus. Lesions noted in the brainstem were typical for 
the paraneoplastic inflammation reported in this condition. These lesions improved after 
treatment with cladribine. They remained stable while on treatment with intravenous immune 
globulin. © 2015 S. Karger AG, Basel 
31 
 
Case Rep Neurol 2015;7:30–38 
DOI: 10.1159/000380760 
 
© 2015 S. Karger AG, Basel 
www.karger.com/crn 
Dardis et al.: Langerhans Cell Histiocytosis in an Adult with Involvement of the 
Calvarium, Cerebral Cortex and Brainstem 
 
 
 
Introduction 
Langerhans cell histiocytosis (LCH) refers to a clonal, neoplastic expansion of Langer-
hans cells. Stimulation by tumor necrosis factor α and granulocyte-monocyte colony-
stimulating factor has been implicated in the pathogenesis (as has human herpesvirus 6). It 
most commonly affects children between the age of 1 and 4, although cases have been de-
scribed in all age groups; the incidence in pediatrics has been estimated at 2–5 per mil-
lion/year [1]. 
It is exceptional for LCH to present with brain involvement as the sole presenting symp-
tom. This complication is reported as occurring in 1–4% of patients with multisystem dis-
ease, typically 5–20 years from the initial diagnosis. It is thought to be more common in men 
(2:1) [2]. Brain involvement has been noted to be more common in those with skull lesions 
[1].  
Case Report 
Our patient was a 64-year-old, right-handed man. The time course of his illness is sum-
marized in table 1. His symptoms began 2 years before his presentation to our service. He 
developed depression, anxiety and agitation, which led to his retirement from construction 
work. Shortly thereafter, he developed episodes described as hyperventilation, lasting from 
seconds to minutes, mostly in the morning, which were followed by confusion and a severe 
‘pounding’ headache affecting the whole head, both of which lasted for hours. 
One year prior to presentation, his family described personality changes (it was hard for 
them to characterize this further) and worsening confusion, particularly over the preceding 
3 months. When these changes began, he was diagnosed with hypothyroidism and diabetes 
insipidus. 
Three months before presentation, he developed weakness of the right leg, which had 
been slowly progressing since. Two weeks prior, it became so bad that he needed help walk-
ing. At this time, he also noticed weakness of the right arm and slurring of speech, which led 
him to seek medical help.  
He had been diagnosed with peripheral arterial disease (claudication in his left leg) 4 
months prior to presentation, and paroxysmal atrial fibrillation 1 month prior, for which he 
was taking warfarin. He continued to smoke 2–3 cigarettes a week. His initial review of sys-
tems revealed that he was anorexic and had lost 30 lb over the last 2 years. He also com-
plained of a loss of libido and an occasional shortness of breath when walking.  
On initial exam, he was unable to sustain upward gaze; vertical saccades were followed 
by a slow downward drift, then a compensatory saccade. He had a weakness of the right side 
of his face, sparing the forehead. He was weak throughout, with strength of 4–/5 on his right 
side in an upper motor neuron pattern with signs of spasticity; Babinski’s reflex was present 
on this side. The left side was 4+/5, with a similar pattern. Cerebellar function and sensation 
were unimpaired.  
His initial complete blood count, comprehensive metabolic panel, serum protein elec-
trophoresis and folate were normal apart from a white cell count of 13 × 109/l (95% neutro-
phils) and platelets of 570 × 109/l. His sodium was initially normal, but, during his admis-
sion, it was generally in the range of 145–160 mmol/l. 
His international normalized ratio was 2.9; the C-reactive protein was 30 mg/l (<10), 
and the erythrocyte sedimentation rate 60 mm/h (<20). His B12 level was low at 375 pg/ml 
(>400). He was hypothyroid with a thyroid-stimulating hormone (TSH) level of 5.6 μIU/ml 
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(<4.9) and a free T4 of 0.6 ng/dl (>0.7). He had hypogonadism (presumably secondary) with 
total testosterone of <20 ng/dl (>200). His morning cortisol and ACTH levels were normal. 
Additional pituitary tests were deferred.  
A lumbar puncture was done shortly after admission, showing 4 red cells, 9 white cells 
(56% lymphocytes, 43% macrophages), and a protein level of 45 mg/dl (<35). His glucose 
was normal as was his IgG synthesis rate. Oligoclonal bands were absent and cytology 
showed no signs of malignancy. 
Shortly after admission, a complete serum paraneoplastic panel was sent; this was nega-
tive. The antibodies reported were: anti-neuronal nuclear types 1–3, anti-glial nuclear type 
1, Purkinje cell types 1–2 and type Tr, amphiphysin, CRMP-5-IgG, striatal, T/Q and N-type 
calcium channels, ACh receptor-binding, ACh receptor ganglionic and neuronal voltage-gated 
K+ channels. 
Brain images on presentation are shown on the left in fig. 1a–f. A CT showed lytic bone 
skull lesions. MRI is notable for the presence of T2-hyperintense lesions in the left frontal 
lobe, the right mesial temporal lobe and the brainstem, which were minimally enhanced. An 
MR perfusion scan of the brain showed no significant increase in relative blood volume or 
relative blood flow in these lesions. A CT of the thorax, abdomen and pelvis showed 5 small 
lung nodules (maximum diameter 6 mm) and a pneumatocele in the left lower lobe. As there 
was nothing further on history, exam or initial investigations to suggest cancer anywhere 
else, a PET/CT was not performed.  
A biopsy of the left frontal bone lesion was performed. This is shown in figure 2. Im-
munohistochemistry shows the lesion to be CD1a- and S100-positive, which is characteristic 
for histiocytosis.  
Initially, we were unsure of the cause of his right temporal lesion. Given the rarity of 
LCH with onset in the central nervous system (CNS) in adults, the possibility of another tu-
mor was raised, and so a second biopsy was performed. In retrospect, it would have been 
better to avoid performing this, as the diagnosis was already clear and his other lesions were 
attributable to LCH. Furthermore, the procedure precipitated  status epilepticus and led to 
preventable complications which ultimately contributed to his death. The biopsy is shown in 
figure 3. This illustrates mild edema, hypercellularity and reactive changes, all of which are 
consistent with the edge of an inflammatory process. No Langerhans or neoplastic cells are 
seen. 
Following the biopsy, it was necessary to induce coma to control his seizures. He was al-
so re-intubated. Septic shock (likely due to ventilator-associated pneumonia) and a pulmo-
nary embolism complicated his course thereafter. He remained intubated for 3 weeks. At the 
end of this period, he was given methylprednisone 1,000 mg i.v. for 3 days, with no sign of 
improvement. Thereafter, he started cladribine 1.4 mg/m2/day for 5 days. Cycles were 
planned every 3 weeks, but delayed due to pancytopenia and infection. He remained clinical-
ly stable after 4 cycles of this regimen. Histiocytosis affecting his skull was thought to be in 
remission as a result of the treatment, as there was no sign of new or enlarging lytic lesions. 
After discharge from the ICU, he showed signs of critical illness myopathy/neuropathy. 
There was widespread muscle atrophy and generalized weakness. He was unable to stand 
without support and his tracheostomy remained in place. 
Given the suspicion of paraneoplastic brainstem inflammation, he was started on intra-
venous immune globulin (IVIG) 400 mg/kg × 5 days. Two weeks after the initial treatment, 
the brainstem showed some improvement in the degree of FLAIR hyperintensity (fig. 1i, j). 
An MRI 1 month after a second course of IVIG showed these changes to be stable overall, 
with some increase in pontine enhancement (fig. 1k, l). 
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He then developed recurrent pneumonia and septic shock, again requiring an ICU ad-
mission. Following this, his family elected a palliative approach to care and he died 6 months 
after his initial presentation.  
Discussion 
Our patient’s episodes of hyperventilation followed by confusion are typical for seizures 
involving the right mesial temporal lobe; the similarity to panic attacks has previously been 
identified in a case series [3]. The development of  status epilepticus following biopsy of this 
region lends support to this being an epileptogenic focus.  
In his cerebrospinal fluid (CSF), the finding of a high proportion of macrophages is strik-
ing. We were unable to find literature specifically addressing the significance of this finding; 
classically it is said to be associated with meningitis due to fungi or tuberculosis [4]. None of 
the other case reports we studied, including one with Langerhans cells in the CSF, reported 
this finding [5]. One series has shown elevations of neurofilament protein light chain, glial 
fibrillary acid protein and total tau protein in the CSF of patients with LCH affecting the brain 
[6]. 
Treatment of adults with LCH has recently been the subject of expert panel recommen-
dations [7]. These advise the use of cladribine for patients such as ours with multisystem 
and CNS involvement (cytarabine is thought be a reasonable alternative). Typically, 6–12 
monthly cycles are recommended with an assessment after 2–3 cycles. Myelosuppression is 
the main dose-limiting toxicity; this has best been studied in the setting of hairy cell leuke-
mia where neutropenia was reported in 70%, anemia (Hb <8 g/dl) in 35% and thrombocy-
topenia in 10% of patients [8]. 
The most recent and thorough description of the neuropathology of LCH comes from a 
series of 12 cases from Grois et al. [9] in 2005 (of note, 2 of these 12 presented with CNS 
involvement). The authors divide the pathology into 3 categories: (1) the typical circum-
scribed granulomas found in other organs; (2) infiltrating granulomas with profound T-cell 
dominated inflammation and severe neurodegeneration; (3) neurodegenerative lesions lack-
ing Langerhans cells, typically affecting the brainstem and cerebellum and resembling para-
neoplastic encephalitis. It appears that the temporal and frontal lesions in our patient were 
of the second type; it is probable that the biopsy came from the neurodegenerative part of 
the lesion rather than that containing Langerhans cells. The MRI appearances of the brain-
stem in our patient are typical of the third type. 
The presence of inflammation without Langerhans cells has led to the view that these le-
sions are paraneoplastic in origin and that the neurodegeneration seen is thus autoimmune. 
The neoplasm in question here is LCH itself. The Langerhans cells are thought to take up 
normal neuronal antigens, provoking an immune response to these; alternatively, the im-
mune system may target antigens shared by Langerhans cells and microglia. If an antigen is 
involved, the pathology reported by Grois et al. [9] suggests that the inflammation is primari-
ly T-cell mediated rather than humoral. This would suggest a cytoplasmic origin for the anti-
gen. The antigens responsible for this phenomenon have not been identified and thus it was 
to be expected that our patient’s paraneoplastic panel was negative [10]. 
Using multiple immunosuppressants sequentially means that a correlation with the pa-
tient’s response is challenging. Langerhans cells in their normal form are thought to have a 
lifespan of months, and LCH is characteristically a slowly progressive disorder. By contrast, 
cytotoxic T-cells typically have a half-life of 24–48 h when activated. Cladribine leads to DNA 
breakage and a depletion of ATP. When used in the treatment of leukemia and lymphoma, it 
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is typically given every 4 weeks. Thus, the initial doses of cladribine would have been ex-
pected to lead to the death of a majority of neoplastic histiocytes while the T-cell-mediated 
inflammation would have been expected to resume within 3–4 weeks. This is borne out on 
serial MRIs (fig. 1).  
IVIG would not have been expected to affect the viability of Langerhans cells, but should 
have reduced T-cell activity for 3–4 weeks. It leads to a selective decrease in T-cells overall 
and an increase in regulatory T-cells. In children with LCH, IVIG has been reported to con-
tribute to a stabilization of inflammation in 4/5 patients treated and to enable long-term 
remission in 1 case [11, 12]. It has been suggested that IVIG be given prophylactically to pre-
vent the development of CNS complications of LCH, particularly diabetes insipidus, which 
tends to be irreversible [13]. Alternative agents reported to treat the paraneoplastic inflam-
mation in LCH include vincristine/cytarabine and all-trans-retinoic acid. The use of steroids 
in our patient would not have been expected to have had long-lasting effects. 
Bearing the above in mind, as well as the results of treatment in other T-cell-mediated 
paraneoplastic conditions, strong consideration should be given to agents that primarily 
target T-cells: steroids, IVIG, plasma exchange and mycophenolate mofetil or cyclophospha-
mide [14].  
Other paraneoplastic disorders recognized in patients with LCH include cancer-
associated retinopathy and spinocerebellar degeneration. This latter is distinct from that 
affecting the brainstem in our patient.  
Conclusions 
Brain imaging should always be undertaken in an older patient with episodes suggestive 
of seizures, diabetes insipidus of central origin or symptoms suggestive of pituitary dysfunc-
tion. Close attention to bone may be necessary to identify lesions typical of LCH. Once a diag-
nosis of LCH is made, a brain biopsy is not essential if the MRI appearances are typical for 
the inflammatory processes that accompany this condition. 
Paraneoplastic inflammation requires treatment concurrently with LCH. Once LCH ap-
pears stable, prolonged treatment may be needed to prevent recurrence of inflammation. 
IVIG appears to be a reasonable adjunct to cladribine, particularly in a case such as this 
where cytopenias or infections limit the use of conventional chemotherapy. 
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Table 1. Time course of the disease 
    
    
Time 
(approximate) 
Time, 
days 
Event MRI (fig. 1) 
    
    
–2 years  Depression, seizures  
–1 year  Personality changes  
  Diabetes insipidus, hypothyroidism  
–3 months  Worsening confusion  
  Weakness of right leg  
–2 weeks  Weakness of right arm, slurred speech  
0  Presentation to our institution a–f 
Day 2 002 Bone biopsy  
Week 2 013 Resection of right temporal lesion; status epilepticus  
Week 4 022 Extubated  
  Methylprednisone 1,000 mg i.v. ×3 days  
Week 5 034 Cladribine 1.4 mg/kg i.v. ×5 days, cycle 1  
Week 11 076 Cladribine, cycle 2  
3.5 months 108 Cladribine, cycle 3 g, h 
4 months  123 IVIG 400 mg/kg i.v. ×5 days, cycle 1  
4 months  135 IVIG 400 mg/kg i.v., cycle 2 i, j 
 140 Cladribine, cycle 4  
 170  k, l 
6 months 190 Died following respiratory infection  
    
    
Time (days) denotes the day when the treatment ended. All cycles of cladribine and IVIG were 5 days. 
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Fig. 1. Imaging at the time of diagnosis and throughout the course of treatment. See table 1 for timing of 
MRIs relative to disease course and treatment. MRIs are 1.5 T. Left-hand side: imaging on presentation. a 
Axial CT (bone windows) shows lytic lesions affecting the calvarium bilaterally (blue arrows). b En-
hancement of the right mesial temporal lobe. This is the lesion that was biopsied (blue arrow). c, d Pon-
tine inflammation. Post-contrast image (c) shows diffuse, patchy enhancement. FLAIR hyperintensity (d) 
is evident in the pons and the pituitary gland. e, f Left frontal inflammation. FLAIR image (e) shows hyper-
intensity with associated cystic degeneration. The latter is best seen on T1-weighted imaging (f). Right-
hand side: imaging during treatment. g, h Response to cladribine (same day as completed cycle No. 3). 
Improvement in enhancement (g) and FLAIR hyperintensity (h) versus images c and d. i, j Response to 
IVIG (same day as completed cycle No. 2). Enhancement remains stable. Brainstem FLAIR hyperintensity 
improved (j vs. h). One month after the most recent cycle of cladribine. k, l Disease stable (no treatment 
for 30 days). Some worsening of pontine enhancement, although not as marked as when the patient first 
presented (k vs. c). 
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Fig. 2. Left frontal bone biopsy. Images labeled top to bottom. a Magnification is ×40. HE staining. Langer-
hans cells are visible as large, oval, mononuclear cells with coffee-bean-shaped nuclei and moderately 
abundant, slightly eosinophilic cytoplasm. The nucleus is prominent with fine chromatin and thin nuclear 
membranes with grooved, folded, or indented nuclear contours, imparting a ‘twisted towel’ or ‘coffee 
bean’ appearance. There are few cytoplasmic vacuoles, little or no phagocytic material and no dendritic 
processes. Many such cells are seen and 2 good examples are highlighted (blue arrows). b CD1a staining 
shows a diffuse uptake by Langerhans cells. c S-100 staining for Langerhans cells is strongly positive.  
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Fig. 3. Right temporal lobe biopsy. HE staining. Magnification is ×40. Mildly hypercellular and gliotic gray 
matter with focal reactive changes. No neoplasia is seen. 
 
